Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-Arm, Open-Label, Dose-Escalation and Expansion Study of HWS116 Injection in Advanced Solid Tumors

NCT07413328 is registered in ClinicalTrials.gov with Wuhan Humanwell Innovative Drug Research and Development Center Limited Company as lead sponsor.

NCT NCT07413328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07413328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-Arm, Open-Label, Dose-Escalation and Expansion Study of HWS116 Injection in Advanced Solid Tumors
Lead sponsor
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase
Phase 1
Overall status
Recruiting
Start date
April 7, 2026
Completion date
February 28, 2028
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors